Skip to main content

Peer Review reports

From: Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial

Original Submission
14 Jun 2021 Submitted Original manuscript
25 Oct 2021 Reviewed Reviewer Report - Yang Xu
1 Nov 2021 Reviewed Reviewer Report - Alex Wright-Hughes
11 Nov 2021 Reviewed Reviewer Report - Philip Pallmann
11 Dec 2021 Author responded Author comments - Liping Dou
Resubmission - Version 2
11 Dec 2021 Submitted Manuscript version 2
22 Dec 2021 Reviewed Reviewer Report - Alex Wright-Hughes
26 Dec 2021 Reviewed Reviewer Report - Yang Xu
14 Jan 2022 Reviewed Reviewer Report - Philip Pallmann
11 Feb 2022 Author responded Author comments - Liping Dou
Resubmission - Version 3
11 Feb 2022 Submitted Manuscript version 3
4 Mar 2022 Reviewed Reviewer Report - Alex Wright-Hughes
3 Apr 2022 Author responded Author comments - Liping Dou
Resubmission - Version 4
3 Apr 2022 Submitted Manuscript version 4
Publishing
25 May 2022 Editorially accepted
6 Jun 2022 Article published 10.1186/s13063-022-06426-2

You can find further information about peer review here.

Back to article page